Jazz Pharmaceuticals
JAZZ
416 hedge funds and large institutions have $7.16B invested in Jazz Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 159 increasing their positions, 144 reducing their positions, and 60 closing their positions.
38% more call options, than puts
Call options by funds: $30M | Put options by funds: $21.7M
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
10% more repeat investments, than reductions
Existing positions increased: 159 | Existing positions reduced: 144
3% less capital invested
Capital invested by funds: $7.37B → $7.16B (-$203M)
1.49% less ownership
Funds ownership: 90.42% → 88.93% (-1.5%)
3% less funds holding
Funds holding: 427 → 416 (-11)
10% less first-time investments, than exits
New positions opened: 54 | Existing positions closed: 60
Top Buyers
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
+$254M |
| 2 |
Renaissance Technologies
New York
|
+$75.6M |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$50.2M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$45.3M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$23.3M |
Top Sellers
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$90.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$74.5M |
| 3 |
APG Asset Management
Amsterdam,
Netherlands
|
-$47M |
| 4 |
Bank of New York Mellon
New York
|
-$44.2M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$30.1M |
JAZZ Hedge Fund Activity: Q2 2019 in Review
416 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q2 2019, worth a combined $7.16B — down 2.8% from $7.37B a quarter earlier.
Sellers outnumbered buyers: 60 funds closed out of JAZZ and 54 opened new positions — a net loss of 6 holders — while 144 trimmed existing stakes and 159 added.
The largest buyer was Nuveen, adding an estimated $254M. The largest seller was Viking Global Investors, exiting entirely with an estimated $90.9M sold.
- 416 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q2 2019, down from 427 in Q1 2019.
- Funds reported $7.16B of Jazz Pharmaceuticals stock for Q2 2019, down 2.8% quarter-over-quarter.
- 54 funds opened new Jazz Pharmaceuticals positions in Q2 2019 and 60 closed out, a net change of -6 holders.
- The largest Jazz Pharmaceuticals buyer in Q2 2019 was Nuveen, an estimated $254M added.
- The largest Jazz Pharmaceuticals seller in Q2 2019 was Viking Global Investors, an estimated $90.9M sold.
Based on aggregated 13F filings for Q2 2019.